Highlighting High Growth Tech Stocks In November 2024

In the wake of a "red sweep" in the U.S. elections, global markets have seen significant shifts, with major indices like the Russell 2000 and S&P 500 experiencing notable gains due to investor optimism about potential economic growth and regulatory changes. As small-cap stocks rally amidst these developments, identifying high-growth tech stocks becomes crucial for investors looking to capitalize on market momentum; such stocks often exhibit strong innovation potential and adaptability to changing economic landscapes.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Material Group	20.45%	24.01%	★★★★★★
Yggdrazil Group	24.66%	85.53%	★★★★★★
eWeLLLtd	26.52%	27.53%	★★★★★★
Ascelia Pharma	76.15%	47.16%	★★★★★★
Medley	26.75%	31.99%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
Alkami Technology	21.89%	98.60%	★★★★★★
Mental Health TechnologiesLtd	27.88%	79.61%	★★★★★★
TG Therapeutics	34.66%	56.48%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 1279 stocks from our High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Celltrion (KOSE:A068270)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Celltrion, Inc., along with its subsidiaries, focuses on developing and producing protein-based drugs for oncology treatment in South Korea and has a market capitalization of approximately ₩34.34 trillion.

Operations: Celltrion, Inc. generates revenue primarily from two segments: Chemical Drugs and Bio Medical Supply, with the latter contributing significantly more at ₩3.54 trillion. The company specializes in protein-based oncology treatments within South Korea.

Despite a challenging year with earnings down by 40.4%, Celltrion's future looks promising, underscored by a robust pipeline and strategic buybacks. The company has committed to repurchasing up to 537,924 shares to stabilize stock prices and enhance shareholder value, reflecting confidence in its financial health. Moreover, Celltrion is poised for significant growth with expected annual revenue and earnings growth rates of 26.3% and 61%, respectively—outpacing the Korean market projections substantially. This growth trajectory is supported by recent approvals like ZYMFENTRA® in the U.S., enhancing its competitive edge in biologics for inflammatory diseases.

• Navigate through the intricacies of Celltrion with our comprehensive health report here.

• Gain insights into Celltrion's historical performance by reviewing our past performance report.

Sonata Software (NSEI:SONATSOFTW)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sonata Software Limited, along with its subsidiaries, offers information technology services and solutions across various regions including the United States, Europe, the Middle East, Asia, India, and Australia with a market capitalization of ₹159.30 billion.

Operations: Sonata Software focuses on providing a wide range of information technology services and solutions globally. Its revenue streams are diversified across several regions, contributing to its substantial market presence. The company emphasizes delivering IT services that cater to various industry needs, leveraging its expertise in software development and digital transformation.

Amidst a backdrop of robust demand for digital transformation solutions, Sonata Software has demonstrated resilience and strategic growth. With a notable revenue increase of 13.9% year-over-year, the company outpaces the broader Indian market's growth rate of 10.5%. This performance is further underscored by an ambitious R&D commitment, which not only fuels innovation but also aligns with projected earnings growth of 31.3% annually—significantly higher than the market average of 17.9%. However, challenges persist as evidenced by a one-off loss impacting financial results and a dip in net profit margins from 5.9% to 2.9%. Despite these hurdles, Sonata Software's recent selection by major global clients for transformative projects in retail and manufacturing sectors highlights its capability to leverage deep tech expertise in fostering substantial business advancements and client relationships.

• Click here and access our complete health analysis report to understand the dynamics of Sonata Software.

• Explore historical data to track Sonata Software's performance over time in our Past section.

Kadokawa (TSE:9468)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Kadokawa Corporation is an entertainment company based in Japan with a market capitalization of approximately ¥393.37 billion.

Operations: The company generates revenue primarily through its publishing, film, and digital content businesses. It focuses on producing and distributing a wide range of media content, including books, magazines, films, anime, and video games.

Kadokawa stands out in the media sector with its strategic focus on innovation and market adaptation. The company's earnings have surged by 65.2% over the past year, significantly outpacing the industry's growth of 5%. This impressive performance is supported by a robust forecast of earnings growth at 24.1% annually, which eclipses the Japanese market's average of 8%. Additionally, Kadokawa has committed to enhancing its competitive edge through increased R&D spending, which now represents a substantial portion of its revenue, aligning closely with its revenue growth projections of 6.9% per year—faster than the market average of 4.2%. Despite challenges such as a volatile share price in recent months, Kadokawa’s ability to maintain high-quality earnings and adapt swiftly to changing market dynamics positions it well for sustained future growth within the tech-driven landscape of modern media.

• Take a closer look at Kadokawa's potential here in our health report.

• Examine Kadokawa's past performance report to understand how it has performed in the past.

Where To Now?

• Unlock more gems! Our High Growth Tech and AI Stocks screener has unearthed 1276 more companies for you to explore.Click here to unveil our expertly curated list of 1279 High Growth Tech and AI Stocks.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com